{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:39:16Z","timestamp":1707525556923},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.7759\/cureus.51412","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T19:58:28Z","timestamp":1704052708000},"source":"Crossref","is-referenced-by-count":0,"title":["Reactivation of Herpes Zoster in a Young Patient With Multiple Sclerosis Under Dimethyl Fumarate Treatment and Normal Lymphocyte Subsets Count: A Case Report"],"prefix":"10.7759","author":[{"given":"Razan Z","family":"AlShammari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah A","family":"AlOqayli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh K","family":"Alnafeesy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtisam","family":"Al Thubaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-0770-VZVIOT","article-title":"Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates","volume":"125","author":"Kleinschmidt-DeMasters BK","year":"2001","unstructured":"Kleinschmidt-DeMasters BK, Gilden DH. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001, 125:770-80. 10.5858\/2001-125-0770-VZVIOT","journal-title":"Arch Pathol Lab Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312083092306","article-title":"Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus","volume":"309","author":"Weller TH","year":"1983","unstructured":"Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983, 309:1434-40. 10.1056\/NEJM198312083092306","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller NH","year":"2008","unstructured":"Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008, 26:675-97. 10.1016\/j.ncl.2008.03.011","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn BP","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007, 82:1341-9. 10.4065\/82.11.1341","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00715-8","article-title":"Epidemiology of varicella zoster virus and herpes zoster virus in gulf cooperation council countries: a review of the literature","volume":"12","author":"Badur S","year":"2023","unstructured":"Badur S, Ozudogru O, Khalaf M, Ozturk S, Albreiki S, Al Awaidy S, Guzman-Holst A. Epidemiology of varicella zoster virus and herpes zoster virus in gulf cooperation council countries: a review of the literature. Infect Dis Ther. 2023, 12:81-93. 10.1007\/s40121-022-00715-8","journal-title":"Infect Dis Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_933_22","article-title":"Clinical and epidemiological aspects of herpes zoster disease in a primary care setting in Riyadh, Saudi Arabia: a retrospective cohort study","volume":"11","author":"Binsaeedu AS","year":"2022","unstructured":"Binsaeedu AS, Bajaber AO, Muqrad AG, Alendijani YA, Alkhenizan HA, Alsulaiman TA, Alkhenizan AH. Clinical and epidemiological aspects of herpes zoster disease in a primary care setting in Riyadh, Saudi Arabia: a retrospective cohort study. J Family Med Prim Care. 2022, 11:6433-7. 10.4103\/jfmpc.jfmpc_933_22","journal-title":"J Family Med Prim Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman CH","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\". Ann Neurol. 2005, 58:840-6. 10.1002\/ana.20703","journal-title":"Ann Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.865866","article-title":"Environmental factors in multiple sclerosis","volume":"13","author":"Ascherio A","year":"2013","unstructured":"Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013, 13:3-9. 10.1586\/14737175.2013.865866","journal-title":"Expert Rev Neurother"},{"key":"ref9","article-title":"Herpes zoster and multiple sclerosis","volume":"26","author":"Ross RT","year":"1999","unstructured":"Ross RT, Cheang M, Landry G, Klassen L, Doerksen K. Herpes zoster and multiple sclerosis. Can J Neurol Sci. 1999, 26:29-32.","journal-title":"Can J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir239","article-title":"Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study","volume":"204","author":"Kang JH","year":"2011","unstructured":"Kang JH, Sheu JJ, Kao S, Lin HC. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. J Infect Dis. 2011, 204:188-92. 10.1093\/infdis\/jir239","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-017-0569-1","article-title":"Prevalence of a history of prior varicella\/herpes zoster infection in multiple sclerosis","volume":"23","author":"Manouchehrinia A","year":"2017","unstructured":"Manouchehrinia A, Tanasescu R, Kareem H, et al.. Prevalence of a history of prior varicella\/herpes zoster infection in multiple sclerosis. J Neurovirol. 2017, 23:839-44. 10.1007\/s13365-017-0569-1","journal-title":"J Neurovirol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin AM","year":"2008","unstructured":"Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008, 197:S58-60. 10.1086\/522123","journal-title":"J Infect Dis"},{"key":"ref13","unstructured":"TECFIDERATM (dimethyl fumarate) delayed-release capsules, for oral use. (2013). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204063s017lbl.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107710","article-title":"Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature","volume":"219","author":"Russo CD","year":"2021","unstructured":"Russo CD, Scott KA, Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. Pharmacol Ther. 2021, 219:107710. 10.1016\/j.pharmthera.2020.107710","journal-title":"Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000076","article-title":"Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate","volume":"2","author":"Spencer CM","year":"2015","unstructured":"Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015, 2:e76. 10.1212\/NXI.0000000000000076","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001360","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study","volume":"84","author":"Miller DH","year":"2015","unstructured":"Miller DH, Fox RJ, Phillips JT, et al.. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015, 84:1145-52. 10.1212\/WNL.0000000000001360","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-016-0042-8","article-title":"Sustained effect of delayed release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies","volume":"5","author":"Gold R","year":"2016","unstructured":"Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained effect of delayed release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016, 5:45-57. 10.1007\/s40120-016-0042-8","journal-title":"Neurol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01666","article-title":"Increased NK cell count in multiple sclerosis patients treated with dimethyl fumarate: a 2-year longitudinal study","volume":"10","author":"Marastoni D","year":"2019","unstructured":"Marastoni D, Buriani A, Pisani AI, et al.. Increased NK cell count in multiple sclerosis patients treated with dimethyl fumarate: a 2-year longitudinal study. Front Immunol. 2019, 10:1666. 10.3389\/fimmu.2019.01666","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.06.002","article-title":"Effects of dimethyl fumarate on lymphocyte subsets","volume":"4","author":"Berkovich R","year":"2015","unstructured":"Berkovich R, Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. Mult Scler Relat Disord. 2015, 4:339-41. 10.1016\/j.msard.2015.06.002","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000340","article-title":"Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis","volume":"4","author":"Ghadiri M","year":"2017","unstructured":"Ghadiri M, Rezk A, Li R, et al.. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm. 2017, 4:e340. 10.1212\/NXI.0000000000000340","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref21","article-title":"Depletion of CD8+ cells in patients with multiple sclerosis on dimethyl fumarate and its association with shingles","volume":"88","author":"Siddiqui U","year":"2017","unstructured":"Siddiqui U, Sloane J, Egnor E, et al.. Depletion of CD8+ cells in patients with multiple sclerosis on dimethyl fumarate and its association with shingles. Neurol J. 2017, 88:368.","journal-title":"Neurol J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox RJ","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al.. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016, 6:220-9. 10.1212\/CPJ.0000000000000238","journal-title":"Neurol Clin Pract"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice","volume":"92","author":"Mehta D","year":"2019","unstructured":"Mehta D, Miller C, Arnold DL, et al.. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019, 92:e1724-38. 10.1212\/WNL.0000000000007262","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001017","article-title":"Aggressive herpes zoster in young patients with multiple sclerosis under dimethyl fumarate: significance of CD8(+) and natural killer cells","volume":"8","author":"Anagnostouli MC","year":"2021","unstructured":"Anagnostouli MC, Velonakis G, Dalakas MC. Aggressive herpes zoster in young patients with multiple sclerosis under dimethyl fumarate: significance of CD8(+) and natural killer cells. Neurol Neuroimmunol Neuroinflamm. 2021, 8:e1017. 10.1212\/NXI.0000000000001017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211037909","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13\u2009years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","volume":"28","author":"Gold R","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A, et al.. Long-term safety and efficacy of dimethyl fumarate for up to 13\u2009years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022, 28:801-16. 10.1177\/13524585211037909","journal-title":"Mult Scler"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22679","article-title":"Varicella-zoster reactivation in a non-immunized elderly multiple sclerosis patient while on delayed-release dimethyl fumarate with grade 2 lymphopenia and profoundly low CD4+ and CD8+ cell counts: a case report","volume":"14","author":"Daripa B","year":"2022","unstructured":"Daripa B, Lucchese S. Varicella-zoster reactivation in a non-immunized elderly multiple sclerosis patient while on delayed-release dimethyl fumarate with grade 2 lymphopenia and profoundly low CD4+ and CD8+ cell counts: a case report. Cureus. 2022, 14:e22679. 10.7759\/cureus.22679","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000203","article-title":"Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate","volume":"3","author":"Ma BB","year":"2016","unstructured":"Ma BB, Ostrow LW, Newsome SD. Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2016, 3:e203. 10.1212\/NXI.0000000000000203","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231189641","article-title":"High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate","volume":"29","author":"Balshi A","year":"2023","unstructured":"Balshi A, Saart E, Pandeya S, Dempsey J, Baber U, Sloane JA. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate. Mult Scler. 2023, 29:1465-70. 10.1177\/13524585231189641","journal-title":"Mult Scler"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519852100","article-title":"A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence","volume":"25","author":"Diebold M","year":"2019","unstructured":"Diebold M, Altersberger V, D\u00e9card BF, Kappos L, Derfuss T, Lorscheider J. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019, 25:1682-5. 10.1177\/1352458519852100","journal-title":"Mult Scler"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.09.009","article-title":"Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient","volume":"26","author":"Perini P","year":"2018","unstructured":"Perini P, Rinaldi F, Puthenparampil M, Marcon M, Perini F, Gallo P. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. Mult Scler Relat Disord. 2018, 26:68-70. 10.1016\/j.msard.2018.09.009","journal-title":"Mult Scler Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Anderson TC","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, et al.. Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:80-4. 10.15585\/mmwr.mm7103a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref32","unstructured":"Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) In immunocompromised adults aged \u226519 years. (2023). Accessed. December 7, 2023: https:\/\/www.cdc.gov\/shingles\/vaccination\/immunocompromised-adults.html."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018758431","article-title":"Shingrix: the new adjuvanted recombinant herpes zoster vaccine","volume":"52","author":"James SF","year":"2018","unstructured":"James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. Ann Pharmacother. 2018, 52:673-80. 10.1177\/1060028018758431","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/216358-reactivation-of-herpes-zoster-in-a-young-patient-with-multiple-sclerosis-under-dimethyl-fumarate-treatment-and-normal-lymphocyte-subsets-count-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:59Z","timestamp":1707509219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/216358-reactivation-of-herpes-zoster-in-a-young-patient-with-multiple-sclerosis-under-dimethyl-fumarate-treatment-and-normal-lymphocyte-subsets-count-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.51412","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,31]]}}}